No Prescription |
 |
 | ||
|
FUNGOTEK Lamisil |
|
| ||
No Prescription » Prescription Drugs 8 » FUNGOTEK Lamisil Terbinafine hydrochloride which is an antifungal medicine used to treat infections caused by fungi.Terbinafine kills fungi and yeasts by interfering with their cell membranes. It works by stopping fungi from producing a substance called ergosterol which is an essential component of fungal cell membranes. The disruption in production of ergosterol disrupts the cell membrane and causes holes to appear. The cell membranes of fungi are vital for their survival. They keep unwanted substances from entering the cells and stop the contents of the cells from leaking out. As terbinafine causes holes to appear in the cell membranes essential constituents of the fungal cells can leak out. This kills the fungi and hence clears up the infection. Terbinafine cream is applied to the skin to treat a wide range of fungal skin infections. Improvement in symptoms is usually seen after a few days of treatment but the prescribed course should be finished to ensure the infection is completely cured and prevent it returning.What is it used for?Fungal infections of the skin such as those below:Athlete's foot (tinea pedis) Fungal infection of the groin ie jock itch (tinea cruris) Ringworm (tinea corporis) Pityriasis versicolor Yeast infections of the skin eg Candida albicans Buy FUNGOTEK Lamisil and other Prescription Drugs 8 products online at Medstore. Buy Online at Medstore - Click Here!
About FUNGOTEK Lamisil: Product Type: Prescription Drugs 8 FUNGOTEK ( Lamisil Generic Terbinafine ) FUNGOTEK (Lamisil Generic Terbinafine) Lamisil Generic Terbinafine 1% Cream 250mg Tabs 5 gm 14 (2 x 7) Lamisil Generic Terbinafine FUNGOTEK
View more Prescription Drugs 8 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
